openPR Logo
Press release

Veterinary Vaccines Market is Anticipated to Show the Robust Growth by 2024

03-27-2017 03:39 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Veterinary Vaccines Market is Anticipated to Show the Robust

The global veterinary vaccines market is highly consolidated, with the top five vendors accounting for a share of nearly 65% in the overall market in 2015, reports TMR in a new study. Zoetis, Inc., Merck & Co., and Sanofi Aventis, the top three companies in the market collectively held a share of more than 45% of the overall market in the same year.

Obtain Report Details @ http://www.transparencymarketresearch.com/veterinary-vaccines-market.html

Targeted in-licensing and acquisitions, expansion of global manufacturing and supply capacities, and increased investments towards research and development activities are some of the key strategies adopted by leading vendors in the market. A recent instance is the strategic alliance of Sanofi with Boehringer Ingelheim in June 2016. Under this alliance, an exchange of Boehringer Ingelheim’s consumer healthcare (CHC) unit with Sanofi’s animal health business took place.

Rising Prevalence of Zoonotic Diseases and Increased Spending on Companion Animals to Boost Demand for Veterinary Vaccines

In the past few years, factors such as globalization and intense changes in global climate have led to a vast rise in the prevalence of zoonotic diseases globally. To prevent the huge loss of livestock and potential threat to human lives that global outbreaks of several zoonotic diseases cause, there has been a surge in government initiatives aimed at mandating vaccination for companion and farm animals. Active efforts are also undertaken by government and non-government bodies to increase awareness among pet and livestock owners about rampant and hazardous animal diseases, their symptoms, and medication.

Also, the vast surge in the global demand for meat, chicken, eggs, and milk is compelling livestock farmers to pay proper attention to vaccination to ensure the production excellent quality products and thereby keep their businesses sustainable and profitable. In the past few years, pet ownership and the money spent for ensuring health and wellness of companion animals has significantly increased on a global front. According to the national pet owners’ survey of 2015-2016, 65% households in the U.S. own a pet. The pet industry in the U.S. had a valuation of US$ 60.59 bn in 2015 and is expected to rise to US$62.75 bn in 2016.

These factors are collectively expected to have a significant impact on the overall development of the global veterinary vaccines market in the next few years. Moreover, the market is also expected to benefit enormously from the vast rise in research and development activities and increased demand for advanced and more effective veterinary vaccines across the globe.

High Dependence on Government Distribution Channels and Shorter Product Exclusivity to Hamper Growth

National governments play a key role in deciding the profitability of the veterinary vaccines market. For instance, the Government of India purchases foot-and-mouth disease (FMD) vaccines in bulk from manufacturers and supplies it to different parts of the country. Such bilk purchases result in reduced prices of the vaccines, substantially bringing down the profitability of manufacturers.

The short product exclusivity period in the animal healthcare industry, of nearly 3-5 years results in intense competition from cheaper generic substitutes and over-the-counter products. Additionally, strict regulations for product approval and the resulting decline in the number of products that can enter the market limit the overall profitability of the global veterinary vaccines market substantially.

For more information on this report, fill the form @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=215

Live Attenuated Vaccines to Make Sizeable Contribution to Overall Revenues

The global market for veterinary vaccines is expected to expand at a healthy 6.9% CAGR over the period between 2016 and 2024. The market, which had a valuation of US$6,271.8 mn in 2015, is expected to rise to US$11,403.6 mn by 2024. In terms of technology type, the segment of live attenuated vaccines is presently the leading contributor to market’s overall revenues. The segment accounted for over 44% in the global market in 2015. Geography-wise, North America held nearly 37% of the global market’s overall revenues in 2015.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Veterinary Vaccines Market is Anticipated to Show the Robust Growth by 2024 here

News-ID: 483344 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Vaccines

Vaccines Market: Information by Type (Monovalent Vaccines, Multivalent Vaccines) …
Till date, vaccines have majorly contributed to eradicating several severe diseases—smallpox and polio—from the face of the earth. During 1980–90, around millions of people died due to smallpox. Moreover, after the introduction of a worldwide End Polio Campaign, the number of polio cases has reduced to 407 in 2013 from 350,000 in 1988, the CDC. Global vaccines market was valued at USD 30.2 billion in 2018 and is expected to
Global Pet Vaccine Market By Type (Attenuated Live Vaccines, Conjugate Vaccines, …
The Global Pet Vaccine Market 2020 report implement in-depth research of the industry with a focus on the current market trends future prospects. The Global Pet Vaccine Market report aims to provide an overview of Pet Vaccine Market players with detailed market segmentation by product, application and geographical region. It also provides market share and size, revenue forecast, growth opportunity. The most recent trending report Worldwide Pet Vaccine Market Economy
Animal Vaccines Market Report 2018: Segmentation by Product (Attenuated Vaccines …
Global Animal Vaccines market research report provides company profile for Merck & Co., Inc., Zoetis Inc., Ceva Sant Animale, Sanofi S.A., Romvac, Vaxxinova, Biovac, Merial, Anicon Labor GmbH, Nexvet, PHL Associates, Inc., Hygieia Biological Laboratories, Colorado Serum Company, Pfizer, Arko Laboratories, Ltd. Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in
Vaccines & Vaccination Market Report 2018: Segmentation by Type (Subunit vaccine …
Global Vaccines & Vaccination market research report provides company profile for CSL, Emergent BioSolutions, GSK, Johnson & Johnson, Pfizer, Merck, Sanofi, Abbott, AstraZeneca, Bavarian Nordic, Novartis, Bharat Biotech, Bio-Med and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year
Global Veterinary Vaccines Market, By Technology Type (Inactivated Vaccines, Tox …
Veterinary/Animal Vaccines – Ensure good health of human’s best friends Veterinary vaccination enhances the health of animals, thus improving their life expectancies. Most common veterinary vaccines include those for rabies, E. coli, distemper, hepatitis rotavirus, parvovirus, brucellosis, and pinkeye. Various diseases such as foot-and-mouth disease and influenza adversely affect livestock across the globe. Economic losses due to death of livestock is significant as it impacts the supply of dairy products, meat,
Global Veterinary Vaccines Market, By Technology Type (Inactivated Vaccines, Tox …
Veterinary/Animal Vaccines – Ensure good health of human’s best friends Veterinary vaccination enhances the health of animals, thus improving their life expectancies. Most common veterinary vaccines include those for rabies, E. coli, distemper, hepatitis rotavirus, parvovirus, brucellosis, and pinkeye. Various diseases such as foot-and-mouth disease and influenza adversely affect livestock across the globe. Economic losses due to death of livestock is significant as it impacts the supply of dairy products, meat,